IPP Bureau
Balaxi Pharmaceuticals' Hyderabad factory to be operational by March 2024
By IPP Bureau - June 28, 2022
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
HIL to commercialise VCRC Bti bio-larvicide technology for mosquito vector control programs
By IPP Bureau - June 28, 2022
HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
R&D key for the growth of nation: Dr. Mandaviya
By IPP Bureau - June 28, 2022
The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.
Medidata launches new clinical operations technologies to address clinical trial oversight issues
By IPP Bureau - June 28, 2022
Medidata Detect and Rave CTMS Have Improved Study Execution Through Role-Based Monitoring Workflows and Clinical Data Visualization for Hundreds of Customers Across More Than 9,000 Studies
Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv
By IPP Bureau - June 28, 2022
Strengthens investment in channels of the future to expand patient reach
Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer
By IPP Bureau - June 28, 2022
First and only PARP inhibitor to improve invasive disease-free survival in patients
50%+ patients delay cataract surgeries in India: Survey
By IPP Bureau - June 28, 2022
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
PHARMAP 2022 concludes with productive networking of pharma leaders
By IPP Bureau - June 28, 2022
The Congress was held on June, 20-21, 2022 in Berlin, Germany
Dr. Reddy's Laboratories acquires injectable product portfolio from Eton Pharma
By IPP Bureau - June 27, 2022
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Aurobindo Pharma Foundation distributes 15 tri motor bikes to physically challenged persons at Jadcherla, Telangana
By IPP Bureau - June 27, 2022
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
By IPP Bureau - June 27, 2022
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron
By IPP Bureau - June 27, 2022
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Novartis commits US$ 250 million to the fight against NTDs and malaria
By IPP Bureau - June 24, 2022
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer
By IPP Bureau - June 24, 2022
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Vividion Therapeutics names Aleksandra Rizo as President and Head of R&D
By IPP Bureau - June 24, 2022
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
